(NewsDirect)
Faron Pharmaceuticals Limited (AIM:FARN,OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warnerfrom Proactive London after the clinical-stage biopharmaceuticalcompany announced it has initiated Phase 2 of its BEXMAB Study ofBexmarilimab in HMA-failed myelodysplastic syndrome (MDS).
MDS is a group of bone marrow disordersthat results in an inability to produce enough healthy blood cells.
Jalkanen starts by giving a briefsummary of the company's hope for the BEXMAB study, before goingon to reveal more information about its second phase.
He highlights the significant advantage toFaron of the relatively small size of the next phase of the study,which saves the company money at a time when many of its competitorsare suffering financially - something he describes as a "a bigrelief for all of us."
He concludes by giving an overviewof the company's financial position, highlighting the €7.1million raised in late October in a share offering. He adds that"very intense" discussions with potential partners areongoing.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.